ONYX PHARMA - Testing Time Ahead in the Hematological Cancer Space
Despite better uptake of Nexavar (L, RCC, HCC) in Asia-Pacific region, increasing expenses have wiped out the profits. All Hopes tied to the Approval of Carfilzomib (PhIIb, next-generation proteasome inhibitor, Relapsed and Refractory Multiple Myeloma - R/R MM). There are two registration PhIII trials underway and interim data from these studies are expected to be out only in … For more detail, please read our report released on 2nd September, 2011 on ONXX titled “Testing Time Ahead in the Hematological Cancer Space”.
COMPANIES MENTIONED
Onyx Pharma
Onyx Pharma
